As pharma deals with patent cliffs, reduced healthcare spending and increasingly stringent regulations, drug development has become more challenging. New excipients could offer much-needed opportunities, but how can you make the right choice? Dr Rajsekhar Paul, senior scientist at Novartis, shares his views.
